{"changes":[],"country":"US","description":"NGM Bio is a clinical-stage biopharmaceutical developing antibody therapeutics targeting GDF15 signalling. It serves patients suffering from hyperemesis gravidarum and cancer cachexia, two conditions with severely limited treatment options. Its lead program NGM120 is the only GDF15/GFRAL antagonist antibody in clinical development across both indications.","domain":"ngmbio.com","employees":null,"founded":2008,"fundingTotalQuarantined":false,"githubOrg":"ngm-biopharmaceuticals","githubStars":null,"industry":"biotech|therapeutics|liver","investors":[],"lat":37.65354,"lng":-122.416866,"location":"South San Francisco CA","name":"NGM Biopharmaceuticals","rounds":[{"amountQuarantined":false,"amountUsd":122000000,"currency":"USD","date":"2024-07-01","investors":[],"leadInvestor":null,"source":{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-07","status":"attributed","url":null},"status":"attributed","type":"series-a","url":null}],"slug":"ngmbio-com","sources":[{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-07","status":"attributed","url":null},{"fact":"existence","publisher":"ngmbio.com","retrievedAt":"2026-05-07","status":"self-reported","url":"https://ngmbio.com"},{"fact":"description","publisher":"ngmbio.com","retrievedAt":"2026-05-07","status":"self-reported","url":"https://ngmbio.com"}],"stage":"series-a","techStack":["Vercel","Next.js","React","Webpack"],"totalRaisedUsd":122000000,"updatedAt":"2026-05-07"}